Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download VistaSeq Hereditary Cancer Panel
Document related concepts
Population genetics wikipedia , lookup
Frameshift mutation wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Microevolution wikipedia , lookup
Medical genetics wikipedia , lookup
Public health genomics wikipedia , lookup
Cancer epigenetics wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Genetic testing wikipedia , lookup
Genome (book) wikipedia , lookup
Transcript
From a Company You Know and Trust VistaSeqSM 27 multi-gene panel Efficient and cost-effective approach to genetic cancer testing Concise report including interpretation and recommendations Experienced Partners Integrated Genetics: A leader in genetic testing and counseling services for more than 25 years Integrated Oncology: A leader in complex diagnostic, prognostic, and predictive testing services for cancer Together we offer The largest national commercial genetic counseling team with unparalleled services Extensive managed care contracts, helping patients maximize their benefits Pre-authorization services to support you and your patients A network of more than 1,700 patient service centers Ordering VistaSeq Hereditary Cancer Panel Test Code 481220 Specimen Requirements 7 mL whole blood in a lavender-top (EDTA) tube To learn more about VistaSeq Hereditary Cancer Panel, BRCAssure® BRCA1/2 Analysis or other Integrated Genetics and Integrated Oncology genetic tests, please visit www.integratedgenetics.com or www.integratedoncology.com. If you are interested in genetic counseling services, please call 855-GC-CALLS or 855-422-2557. REFERENCES 1.Genetic Testing for Hereditary Cancer Syndromes. Available at the website of the National Cancer Institute (http://www.cancer.gov). Accessed May 15, 2015. 2.Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.2015. Available at: http://www.nccn.org/professionals/ physician_gls/pdf/ genetics_screening.pdf. Accessed May 15, 2015. 3.SGO Clinical Practice Statement: Next Generation Cancer Gene Panels Versus Gene by Gene Testing March 2014. Available at: https://www.sgo.org/clinicalpractice/guidelines/next-generation-cancer-gene-panels-versus-gene-by-gene-testing. Accessed May 18, 2015. 4.Pagon, RA, Adam, MP, Ardinger, HH, et al., editors, GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1116/. Accessed May 15, 2015. 5. Genetics of Breast and Gynecologic Cancers. Available at the website of the National Cancer Institute (http://www.cancer.gov). Accessed May 18, 2015. 6. Ratajska, M et al., Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat 2012; 131:89-97. 7. Garber, J and Offit, K, Hereditary Cancer Predisposition Syndromes. J Clin Oncol 2005; 23:276-92. 8. Rafner, T et al., Mutations in BRIP1 confer high risk of ovarian cancer. Nature Genetics 2011; 43:1104-7. 9. Solyom, S et al., Breast Cancer-Associated Abraxas Mutation Disrupts Nuclear Localization a Damage Response Functions. Sci Transl Med 2012; 4:122ra23. 10.Damiola, F et al., Rare key functional domain missense substitutions in MRE11A, RAD50 and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res 2014; 16(3):R58. 11. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Available at the website of the National Cancer Institute (http://www.cancer.gov). Accessed May 19, 2015. 12. Osher, DJ et al., Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. Br J Cancer 2012; 106(8):1460-3. 13. Banno, K et al., Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review). Oncol Lett 2013; 6(5):1184-8. 14. Cowden Syndrome. Available at the website of Cancer.Net (http://www.cancer.net/cancer-types/cowden-syndrome). Accessed June 3, 2015. 15. Roberts, NJ et al., ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012; 2(1):41. NCCN Guidelines® is a trademark owned by the National Comprehensive Cancer Network, Inc. VistaSeq is a service mark of Laboratory Corporation of America ® Holdings. BRCAssure ® is a registered service mark of Laboratory Corporation of America ® Holdings. ©2015 Laboratory Corporation of America ® Holdings. All rights reserved. gen-265-v1-0815 L14470-0815-1 SM www.integratedgenetics.com www.integratedoncology.com Because Knowledge is a Powerful Tool. VistaSeqSM Hereditary Cancer Panel provides an assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes. Expand your patients’ understanding of their hereditary cancer risk… Because Knowledge is a Powerful Tool Hereditary Cancer Syndromes Identifying Your Patients’ Risk The mapping of the human genome has provided medical professionals with the ability to refine a patient’s cancer risk through an analysis of inherited (germline) mutations. Approximately 5 to 10 percent of cancers are thought to be caused by mutations in genes that are associated with hereditary cancer syndromes.1 VistaSeq Hereditary Cancer Panel is a multi-gene test that detects inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers. Genetic NCCN Guidelines® and The Society of Gynecologic Oncology (SGO) note that hereditary multi-gene panels may be an efficient and cost-effective approach to genetic cancer testing when used in appropriate clinical settings.2,3 mutations have been associated with more than 50 hereditary cancer syndromes.1 Patients with genetic mutations are at a higher risk of developing certain types of cancer than the general population. Genetic tests can help confirm whether a patient’s condition is the result of an inherited cancer syndrome. Genetic tests can also help identify family members at risk for developing cancers associated with a hereditary cancer syndrome. VistaSeq Hereditary Cancer Panel Indications for testing: When a patient’s personal or family medical history suggests a hereditary cancer syndrome hen a patient’s personal or family history includes several W cancer types When a patient has suspicious medical history that does not meet clinical testing criteria for a specific hereditary cancer syndrome When a patient has tested negative or indeterminate for mutations in a single cancer gene but whose personal and/or family history suggests a hereditary predisposition for cancer VistaSeq Hereditary Cancer Panel Mutations in different genes can cause the same type of cancer; conversely, one gene may be associated with multiple hereditary cancers. Genes The NCCN Guidelines® specify that multi-gene testing is ideally offered in consultation with a cancer genetics professional.2 Integrated Genetics and Integrated Oncology provide the largest national commercial genetic counseling team to help patients make informed healthcare decisions. Call us at 855-GC-CALLS or 855-422-2257. APC 4 ATM 4,5,15 BARD16 BMPR1A4,7 BRCA14 BRCA2 4 BRIP15,8 CDH12,4 CDK47 CDKN2A7 CHEK24 EPCAM 4 FAM175A9 MLH14 MSH24 MSH6 4 MUTYH 4 NBN 4,10 PALB2 4,11 PMS2 4 PRKAR1A 4 PTEN 4,14 RAD51C 4 RAD51D12 SMAD44,7 STK114,13 TP534 Breast Colorectal Ovarian Endometrial Gastric Pancreatic Skin Cancer Cancer Cancer Cancer Cancer Cancer Cancer Prostate Other Cancer Cancers hereditary cancer syndromes. provides an assessment of genetic mutations within a panel of 27 genes known to be associated with To confirm a diagnosis of an inherited cancer syndrome identify family members who may have inherited a cancerTo associated mutation T o provide clinicians with an assessment of multiple cancerassociated genes in a cost-effective and timely manner Broadening Your Patients’ Options The VistaSeq Hereditary Cancer Panel is designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers. Patients with a family history that is specific to one cancer type may receive more benefit from a focused genetic test such as BRCAssure® BRCA1/2 analysis or testing for Lynch syndrome. www.integratedgenetics.com www.integratedoncology.com Expand your patients’ understanding of their hereditary cancer risk… Because Knowledge is a Powerful Tool Hereditary Cancer Syndromes Identifying Your Patients’ Risk The mapping of the human genome has provided medical professionals with the ability to refine a patient’s cancer risk through an analysis of inherited (germline) mutations. Approximately 5 to 10 percent of cancers are thought to be caused by mutations in genes that are associated with hereditary cancer syndromes.1 VistaSeq Hereditary Cancer Panel is a multi-gene test that detects inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers. Genetic NCCN Guidelines® and The Society of Gynecologic Oncology (SGO) note that hereditary multi-gene panels may be an efficient and cost-effective approach to genetic cancer testing when used in appropriate clinical settings.2,3 mutations have been associated with more than 50 hereditary cancer syndromes.1 Patients with genetic mutations are at a higher risk of developing certain types of cancer than the general population. Genetic tests can help confirm whether a patient’s condition is the result of an inherited cancer syndrome. Genetic tests can also help identify family members at risk for developing cancers associated with a hereditary cancer syndrome. VistaSeq Hereditary Cancer Panel Indications for testing: When a patient’s personal or family medical history suggests a hereditary cancer syndrome hen a patient’s personal or family history includes several W cancer types When a patient has suspicious medical history that does not meet clinical testing criteria for a specific hereditary cancer syndrome When a patient has tested negative or indeterminate for mutations in a single cancer gene but whose personal and/or family history suggests a hereditary predisposition for cancer VistaSeq Hereditary Cancer Panel Mutations in different genes can cause the same type of cancer; conversely, one gene may be associated with multiple hereditary cancers. Genes The NCCN Guidelines® specify that multi-gene testing is ideally offered in consultation with a cancer genetics professional.2 Integrated Genetics and Integrated Oncology provide the largest national commercial genetic counseling team to help patients make informed healthcare decisions. Call us at 855-GC-CALLS or 855-422-2257. APC 4 ATM 4,5,15 BARD16 BMPR1A4,7 BRCA14 BRCA2 4 BRIP15,8 CDH12,4 CDK47 CDKN2A7 CHEK24 EPCAM 4 FAM175A9 MLH14 MSH24 MSH6 4 MUTYH 4 NBN 4,10 PALB2 4,11 PMS2 4 PRKAR1A 4 PTEN 4,14 RAD51C 4 RAD51D12 SMAD44,7 STK114,13 TP534 Breast Colorectal Ovarian Endometrial Gastric Pancreatic Skin Cancer Cancer Cancer Cancer Cancer Cancer Cancer Prostate Other Cancer Cancers hereditary cancer syndromes. provides an assessment of genetic mutations within a panel of 27 genes known to be associated with To confirm a diagnosis of an inherited cancer syndrome identify family members who may have inherited a cancerTo associated mutation T o provide clinicians with an assessment of multiple cancerassociated genes in a cost-effective and timely manner Broadening Your Patients’ Options The VistaSeq Hereditary Cancer Panel is designed to provide information that can be used to determine if there is an increased cancer risk in patients with an associated personal or family history. It is specifically designed to detect inherited mutations and is not appropriate for the detection of other types of mutations in acquired cancers. Patients with a family history that is specific to one cancer type may receive more benefit from a focused genetic test such as BRCAssure® BRCA1/2 analysis or testing for Lynch syndrome. www.integratedgenetics.com www.integratedoncology.com From a Company You Know and Trust VistaSeqSM 27 multi-gene panel Efficient and cost-effective approach to genetic cancer testing Concise report including interpretation and recommendations Experienced Partners Integrated Genetics: A leader in genetic testing and counseling services for more than 25 years Integrated Oncology: A leader in complex diagnostic, prognostic, and predictive testing services for cancer Together we offer The largest national commercial genetic counseling team with unparalleled services Extensive managed care contracts, helping patients maximize their benefits Pre-authorization services to support you and your patients A network of more than 1,700 patient service centers Ordering VistaSeq Hereditary Cancer Panel Test Code 481220 Specimen Requirements 7 mL whole blood in a lavender-top (EDTA) tube To learn more about VistaSeq Hereditary Cancer Panel, BRCAssure® BRCA1/2 Analysis or other Integrated Genetics and Integrated Oncology genetic tests, please visit www.integratedgenetics.com or www.integratedoncology.com. If you are interested in genetic counseling services, please call 855-GC-CALLS or 855-422-2557. REFERENCES 1.Genetic Testing for Hereditary Cancer Syndromes. Available at the website of the National Cancer Institute (http://www.cancer.gov). Accessed May 15, 2015. 2.Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.2015. Available at: http://www.nccn.org/professionals/ physician_gls/pdf/ genetics_screening.pdf. Accessed May 15, 2015. 3.SGO Clinical Practice Statement: Next Generation Cancer Gene Panels Versus Gene by Gene Testing March 2014. Available at: https://www.sgo.org/clinicalpractice/guidelines/next-generation-cancer-gene-panels-versus-gene-by-gene-testing. Accessed May 18, 2015. 4.Pagon, RA, Adam, MP, Ardinger, HH, et al., editors, GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1116/. Accessed May 15, 2015. 5. Genetics of Breast and Gynecologic Cancers. Available at the website of the National Cancer Institute (http://www.cancer.gov). Accessed May 18, 2015. 6. Ratajska, M et al., Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat 2012; 131:89-97. 7. Garber, J and Offit, K, Hereditary Cancer Predisposition Syndromes. J Clin Oncol 2005; 23:276-92. 8. Rafner, T et al., Mutations in BRIP1 confer high risk of ovarian cancer. Nature Genetics 2011; 43:1104-7. 9. Solyom, S et al., Breast Cancer-Associated Abraxas Mutation Disrupts Nuclear Localization a Damage Response Functions. Sci Transl Med 2012; 4:122ra23. 10.Damiola, F et al., Rare key functional domain missense substitutions in MRE11A, RAD50 and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res 2014; 16(3):R58. 11. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Available at the website of the National Cancer Institute (http://www.cancer.gov). Accessed May 19, 2015. 12. Osher, DJ et al., Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. Br J Cancer 2012; 106(8):1460-3. 13. Banno, K et al., Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review). Oncol Lett 2013; 6(5):1184-8. 14. Cowden Syndrome. Available at the website of Cancer.Net (http://www.cancer.net/cancer-types/cowden-syndrome). Accessed June 3, 2015. 15. Roberts, NJ et al., ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012; 2(1):41. NCCN Guidelines® is a trademark owned by the National Comprehensive Cancer Network, Inc. VistaSeq is a service mark of Laboratory Corporation of America ® Holdings. BRCAssure ® is a registered service mark of Laboratory Corporation of America ® Holdings. ©2015 Laboratory Corporation of America ® Holdings. All rights reserved. gen-265-v1-0815 L14470-0815-1 SM www.integratedgenetics.com www.integratedoncology.com Because Knowledge is a Powerful Tool. VistaSeqSM Hereditary Cancer Panel provides an assessment of genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes.
